Inherited platelet disorders: A clinical approach to diagnosis and management

Expert Review of Hematology

Volumn 4, Issue 4, 2011, Pages 455-472

  Cox, Kelly ^a   Price, Victoria ^a   Kahr, Walter HA ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

diagnosis of inherited platelet disorders; platelet laboratory evaluation; thrombocytopenia; treatment

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; CYTOSKELETON PROTEIN; DESMOPRESSIN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN; GLYCOPROTEIN 6; GLYCOPROTEIN 9; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IB BETA; GLYCOPROTEIN V; HOMEOBOX PROTEIN HOX A11; HOMEODOMAIN PROTEIN; LYSINE DERIVATIVE; MEMBRANE PROTEIN; MYOSIN IIA; NEURAL WISKOTT ALDRICH SYNDROME PROTEIN; PROCOAGULANT; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT THROMBIN; THROMBOCYTE RECEPTOR; THROMBOPOIETIN RECEPTOR; THROMBOXANE A2 RECEPTOR; TRANEXAMIC ACID; TRANSCRIPTION FACTOR GATA 1; TRANSMEMBRANE PROTEIN 16F; UNCLASSIFIED DRUG; UROKINASE;

ADENOSINE DIPHOSPHATE RECEPTOR DEFECT; ARTHROGRYPOSIS; ARTHROGRYPOSIS RENAL DYSFUNCTION AND CHOLESTASIS SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNE THROMBOCYTOPENIA; BERNARD SOULIER DISEASE; BLEEDING; BLEEDING DISORDER; BLOOD CELL COUNT; CHEDIAK HIGASHI SYNDROME; CHOLESTASIS; CHROMOSOME 11Q; CHROMOSOME DELETION 22Q11; CLINICAL FEATURE; COLLAGEN RECEPTOR DEFECT; COMBINED ALPHA DELTA GRANULE DISORDER; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; DELTA GRANULE PLATELET DEFECT; DIARRHEA; DIGEORGE SYNDROME; DISEASE CLASSIFICATION; DRUG MEGADOSE; EPISTAXIS; FECHTNER SYNDROME; FLUID RETENTION; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE THERAPY; GLANZMANN DISEASE; GRAY PLATELET SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPONATREMIA; JACOBSEN SYNDROME; KIDNEY DYSFUNCTION; LABORATORY DIAGNOSIS; LIFESTYLE MODIFICATION; MAY HEGGLIN ANOMALY; MISSENSE MUTATION; MUCOCUTANEOUS BLEEDING; MUCOSAL BLEEDING; NAUSEA; NEPHROTIC SYNDROME; NONSYNDROMIC DELTA GRANULE DISORDER; OCULAR ALBINISM; ORAL BLEEDING; PATHOGENESIS; PATIENT EDUCATION; PHYSICAL EXAMINATION; PLATELET TYPE VON WILLEBRAND DISEASE; PRIORITY JOURNAL; PROTEIN DEFECT; QUEBEC PLATELET DISORDER; RADIOULNAR SYNOSTOSIS WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA; REPEATED DRUG DOSE; REVIEW; SCOTT SYNDROME; SEBASTIAN SYNDROME; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPENIA WITH ABSENT RADII SYNDROME; THROMBOSIS; THROMBOXANE PROSTANOID RECEPTOR DEFECT; VELOCARDIOFACIAL SYNDROME; VISION; VON WILLEBRAND DISEASE; WISKOTT ALDRICH SYNDROME; X LINKED THROMBOCYTOPENIA WITH DYSERYTHROPOIESIS;

BLOOD COAGULATION DISORDERS; BLOOD PLATELET DISORDERS; HUMANS;

EID: 79961094789     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.41     Document Type: Review

References (140)

1. Rao AK. Inherited defects in platelet signaling mechanisms. J. Thromb. Haemost. 1(4), 671-681 (2003).
2. Lanza F. Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).Orphanet. J. Rare Dis. 1, 46 (2006).
3. Lopez JA, Andrews RK, Afshar- Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 91(12), 4397-4418 (1998). (Pubitemid 28270285)
4. Savoia A, Balduini CL, Savino M et al. Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard- Soulier syndrome. Blood 97(5), 1330-1335 (2001). (Pubitemid 32183756)
5. Di Minno G, Coppola A, Di Minno MN, Poon MC. Glanzmann's thrombasthenia (defective platelet integrin aIIb-b3): proposals for management between evidence and open issues. Thromb. Haemost. 102(6), 1157-1164 (2009).
6. Ouakaa-Kchaou A, Gargouri D, Elloumi H, Kharrat J, Ghorbel A. Intractable gastrointestinal bleeding from angiodysplasia in a patient with Bernard- Soulier syndrome. Ann. Hematol. 90(7), 861-862 (2011).
7. Bolton-Maggs PH, Chalmers EA, Collins PW et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br. J. Haematol. 135(5), 603-633 (2006). (Pubitemid 44674072)
8. Nurden AT. Qualitative disorders of platelets and megakaryocytes. J. Thromb. Haemos. 3(8), 1773-1782 (2005). (Pubitemid 41716564)
9. Nurden AT, Nurden P. Inherited disorders of platelets: an update. Curr. Opin. Hematol. 13(3), 157-162 (2006).
10. Salles, II, Feys HB, Iserbyt BF, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Inherited traits affecting platelet function. Blood Rev. 22(3), 155-172 (2008).
11. Berndt MC, Andrews RK. Bernard-Soulier syndrome. Haematologica 96(3), 355-359 (2011).
12. Kahn ML, Diacovo TG, Bainton DF, Lanza F, Trejo J, Coughlin SR. Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and do not exhibit a Bernard-Soulier phenotype. Blood 94(12), 4112-4121 (1999).
13. Nurden AT, Caen JP. Specific roles for platelet surface glycoproteins in platelet function. Nature 255(5511), 720-722 (1975).
14. Savoia A, Pastore A, De Rocco D et al. Clinical and genetic aspects of Bernard- Soulier syndrome: searching for genotype/ phenotype correlations. Haematologica 96(3), 417-423 (2011).
15. Wei AH, Schoenwaelder SM, Andrews RK, Jackson SP. New insights into the haemostatic function of platelets. Br. J. Haematol. 147(4), 415-430 (2009).
16. Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb. Haemost. 99(2), 253-263 (2008). (Pubitemid 351230953)
17. Ruggeri ZM. Platelet adhesion under flow. Microcirculation 16(1), 58-83 (2009).
18. Beguin S, Keularts I, Al Dieri R, Bellucci S, Caen J, Hemker HC. Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard- Soulier syndrome. J. Thromb. Haemost. 2(1), 170-176 (2004). (Pubitemid 40185634)
19. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J. Thromb. Haemost. 4(2), 312-319 (2006).
20. Alamelu J, Liesner R. Modern management of severe platelet function disorders. Br. J. Haematol. 149(6), 813-823 (2010).
21. Oskarsdottir S, Persson C, Eriksson BO, Fasth A. Presenting phenotype in 100 children with the 22q11 deletion syndrome. Eur. J. Pediatr. 4(3), 146-153 (2005). (Pubitemid 40558177)
22. Liang HP, Morel-Kopp MC, Curtin J et al. Heterozygous loss of platelet glycoprotein (GP) Ib-V-IX variably affects platelet function in velocardiofacial syndrome (VCFS) patients. Thromb. Haemost. 98(6), 1298-1308 (2007). (Pubitemid 350239102)
23. Budarf ML, Konkle BA, Ludlow LB et al. Identification of a patient with Bernard- Soulier syndrome and a deletion in the DiGeorge/velo-cardio-facial chromosomal region in 22q11.2. Hum. Mol. Genet. 4(4), 763-766 (1995).
24. Federici AB, Mannucci PM, Castaman G et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 113(3), 526-534 (2009).
25. Othman M, Favaloro EJ. Genetics of type 2B von Willebrand disease: 'true 2B,' 'tricky 2B,' or 'not 2B.' What are the modifiers of the phenotype? Semin. Thromb. Hemost. 34(6), 520-531 (2008).
26. Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin. Thromb. Hemost. 34(1), 113-127 (2008).
27. Othman M. Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes. Semin. Thromb. Hemost. 33(8), 780-786 (2007). (Pubitemid 351158446)
28. Othman M, Notley C, Lavender FL et al. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease. Blood 105(11), 4330-4336 (2005). (Pubitemid 40720779)
29. Enayat MS, Guilliatt AM, Lester W, Wilde JT, Williams MD, Hill FG. Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance. Br. J. Haematol. 133(6), 664-666 (2006). (Pubitemid 43742784)
30. Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am. J. Hematol. 77(2), 198-199 (2004). (Pubitemid 39281870)
31. Nurden AT. Glanzmann thrombasthenia. Orphanet. J. Rare. Dis. 1, 10 (2006).
32. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 75(7), 1383-1395 (1990). (Pubitemid 20114873)
33. Bellucci S, Caen J. Molecular basis of Glanzmann's thrombasthenia and current strategies in treatment. Blood Rev. 16(3), 193-202 (2002). (Pubitemid 34982976)
34. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin aIIbb3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 112(8), 3011-3025 (2008).
35. Israels SJ, Kahr WH, Blanchette VS, Luban NL, Rivard GE, Rand ML. Platelet disorders in children: a diagnostic approach. Pediatr. Blood Cancer 56(6), 975-983 (2011).
36. Cattaneo M, Zighetti ML, Lombardi R et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc. Natl Acad. Sci. USA 100(4), 1978-1983 (2003). (Pubitemid 36254559)
37. Hollopeter G, Jantzen HM, Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409(6817), 202-207 (2001). (Pubitemid 32144286)
38. Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 117(7), 2102-2112 (2011).
39. Cattaneo M. Inherited platelet-based bleeding disorders. J. Thromb. Haemost. 1(7), 1628-1636 (2003).
40. Fabre JE, Nguyen M, Latour A et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat. Med. 5(10), 1199-1202 (1999). (Pubitemid 29474427)
41. Oury C, Toth-Zsamboki E, Van Geet C et al. A natural dominant negative P2X1 receptor due to deletion of a single amino acid residue. J. Biol. Chem. 275(30), 22611-22614 (2000). (Pubitemid 30646139)
42. Nurden A. GPVI: the inside story. Blood 114(9), 1723-1724 (2009).
43. Trifiro E, Williams SA, Cheli Y et al. The low-frequency isoform of platelet glycoprotein VIb attenuates ligand-mediated signal transduction but not receptor expression or ligand binding. Blood 114(9), 1893-1899 (2009).
44. Dumont B, Lasne D, Rothschild C et al. Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations. Blood 114(9), 1900-1903 (2009).
45. Hermans C, Wittevrongel C, Thys C, Smethurst PA, Van Geet C, Freson K. A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder. J. Thromb. Haemost. 7(8), 1356-1363 (2009).
46. Mumford AD, Dawood BB, Daly ME et al. A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood 115(2), 363-369 (2010).
47. Watson S, Daly M, Dawood B et al. Phenotypic approaches to gene mapping in platelet function disorders - identification of new variant of P2Y12, TxA2 and GPVI receptors. Hamostaseologie 30(1), 29-38 (2010).
48. Blair P, Flaumenhaft R. Platelet a-granules: basic biology and clinical correlates. Blood Rev. 23(4), 177-189 (2009).
49. Raccuglia G. Gray platelet syndrome. A variety of qualitative platelet disorder. Am. J. Med. 51(6), 818-828 (1971).
50. Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev. 21(1), 21-36 (2007). (Pubitemid 46097190)
51. Fabbro S, Kahr WH, Hinckley J et al. Homozygosity mapping with SNP arrays confirms 3p21 as a recessive locus for gray platelet syndrome and narrows the interval significantly. Blood 117(12), 3430-3434 (2011).
52. Gunay-Aygun M, Zivony-Elboum Y, Gumruk F et al. Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood 116(23), 4990-5001 (2011).
53. Kahr WHA, Hinckley J, Li L et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat. Genet. DOI: 10.1038/ ng.884 (2011) (Epub ahead of print).
54. Albers CA, Cvejic A, Favier R et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat. Genet. DOI:10.1038/ ng.885 (2011) (Epub ahead of print).
55. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet a-granules. Nat. Genet. DOI:10.1038/ng.883 (2011) (Epub ahead of print).
56. Tubman VN, Levine JE, Campagna DR et al. X-linked gray platelet syndrome due to a GATA1 Arg2.Gln mutation. Blood 109(8), 3297-3299 (2007). (Pubitemid 46572516)
57. Balduini CL, De Candia E, Savoia A. Why the disorder induced by GATA1 Arg2. Gln mutation should be called 'X-linked thrombocytopenia with thalassemia' rather than 'X-linked gray platelet syndrome'. Blood 110(7), 2770-2771; author reply 2771 (2007). (Pubitemid 47523208)
58. Eastham KM, McKiernan PJ, Milford DV et al. ARC syndrome: an expanding range of phenotypes. Arch. Dis. Child. 85(5), 415-420 (2001). (Pubitemid 33702299)
59. Gissen P, Johnson CA, Morgan NV et al. Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat. Genet. 36(4), 400-404 (2004). (Pubitemid 38437264)
60. Hayes JA, Kahr WH, Lo B, Macpherson BA. Liver biopsy complicated by hemorrhage in a patient with ARC syndrome. Paediatr. Anaesth. 14(11), 960-963 (2004). (Pubitemid 39524799)
61. Lo B, Li L, Gissen P et al. Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet a-granule biogenesis. Blood 106(13), 4159-4166 (2005). (Pubitemid 41775922)
62. Tracy PB, Giles AR, Mann KG, Eide LL, Hoogendoorn H, Rivard GE. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J. Clin. Invest. 74(4), 1221-1228 (1984). (Pubitemid 15206817)
63. Hayward CP, Rivard GE, Kane WH et al. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 87(12), 4967-4978 (1996).
64. Janeway CM, Rivard GE, Tracy PB, Mann KG. Factor V Quebec revisited. Blood 87(9), 3571-3578 (1996). (Pubitemid 26129583)
65. Kahr WH, Zheng S, Sheth PM et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 98(2), 257-265 (2001).
66. Sheth PM, Kahr WH, Haq MA, Veljkovic DK, Rivard GE, Hayward CP. Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder. Thromb. Haemost. 90(2), 293-298 (2003). (Pubitemid 36992505)
67. Diamandis M, Veljkovic DK, Maurer-Spurej E, Rivard GE, Hayward CP. Quebec platelet disorder: features, pathogenesis and treatment. Blood Coagul. Fibrinolysis 19(2), 109-119 (2008). (Pubitemid 351252988)
68. Paterson AD, Rommens JM, Bharaj B et al. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood 115(6), 1264-1266 (2010).
69. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 103(2), 390-398 (2004). (Pubitemid 38140065)
70. Favier R, Jondeau K, Boutard P et al. Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new cases. Thromb. Haemost. 90(5), 893-897 (2003). (Pubitemid 37427859)
71. Breton-Gorius J, Favier R, Guichard J et al. A new congenital dysmegakaryopoietic thrombocytopenia (Paris-Trousseau) associated with giant platelet a-granules and chromosome 11 deletion at 11q23. Blood 85(7), 1805-1814 (1995).
72. Raslova H, Komura E, Le Couedic JP et al. FLI1 monoallelic expression combined with its hemizygous loss underlies Paris- Trousseau/Jacobsen thrombopenia. J. Clin. Invest. 114(1), 77-84 (2004). (Pubitemid 39071646)
73. Mattina T, Perrotta CS, Grossfeld P. Jacobsen syndrome. Orphanet. J. Rare Dis. 4, 9 (2009).
74. Reed GL. Platelet secretory mechanisms. Semin. Thromb. Hemost. 30(4), 441-450 (2004). (Pubitemid 39180719)
75. White JG. Use of the electron microscope for diagnosis of platelet disorders. Semin. Thromb. Hemost. 24(2), 163-168 (1998). (Pubitemid 28180827)
76. White JG. Electron microscopy methods for studying platelet structure and function. Methods Mol. Biol. 272, 47-63 (2004).
77. Wall JE, Buijs-Wilts M, Arnold JT et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br. J. Haematol. 89(2), 380-385 (1995).
78. Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu. Rev. Genomics Hum. Genet. 9, 359-386 (2008).
79. Huizing M, Boissy RE, Gahl WA. Hermansky-Pudlak syndrome: vesicle formation from yeast to man. Pigment Cell Res. 15(6), 405-419 (2002). (Pubitemid 35374622)
80. Kaplan J, De Domenico I, Ward DM. Chediak-Higashi syndrome. Curr. Opin. Hematol. 15(1), 22-29 (2008). (Pubitemid 350191025)
81. Trantow CM, Hedberg-Buenz A, Iwashita S, Moore SA, Anderson MG. Elevated oxidative membrane damage associated with genetic modifiers of Lyst-mutant phenotypes. PLoS Genet. 6(7), e1001008 (2010).
82. Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol. Genet. Metab. 68(2), 283-303 (1999). (Pubitemid 29501101)
83. Tolmachova T, Abrink M, Futter CE, Authi KS, Seabra MC. Rab27b regulates number and secretion of platelet dense granules. Proc. Natl Acad. Sci. USA 104(14), 5872-5877 (2007). (Pubitemid 47175626)
84. Masliah-Planchon J, Bellucci S, Darnige L, Callebert J, Fischer AM, Tapon-Bretaudiere J. Absence of mutation in the RAB27B gene in patients with platelet d-storage pool deficiency. Eur. J. Haematol. 86(4), 350-351 (2011).
85. Detter JC, Zhang Q, Mules EH et al. Rab geranylgeranyl transferase amutation in the gunmetal mouse reduces Rab prenylation and platelet synthesis. Proc. Natl Acad. Sci. USA 97(8), 4144-4149 (2000). (Pubitemid 30226101)
86. Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 113(25), 6288-6295 (2009).
87. Thrasher AJ. New insights into the biology of Wiskott-Aldrich syndrome (WAS).Hematology Am. Soc. Hematol. Educ. Program 132-138 (2009).
88. Ochs HD. Mutations of the Wiskott- Aldrich syndrome protein affect protein expression and dictate the clinical phenotypes. Immunol. Res. 44(1-3), 84-88 (2009).
89. Balduini CL, Cattaneo M, Fabris F et al. Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica 88(5), 582-592 (2003). (Pubitemid 36648448)
90. Albert MH, Bittner TC, Nonoyama S et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 115(16), 3231-3238 (2010).
91. Balduini CL, Iolascon A, Savoia A. Inherited thrombocytopenias: from genes to therapy. Haematologica 87(8), 860-880 (2002). (Pubitemid 34851558)
92. Sabri S, Foudi A, Boukour S et al. Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood 108(1), 134-140 (2006). (Pubitemid 43990621)
93. Ochs HD. The Wiskott-Aldrich syndrome. Semin. Hematol. 35(4), 332-345 (1998). (Pubitemid 28477934)
94. Seri M, Pecci A, Di Bari F et al. MYH9- related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 82(3), 203-215 (2003). (Pubitemid 36578709)
95. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin. Thromb. Hemost. 35(2), 189-203 (2009).
96. Leung TF, Tsoi WC, Li CK, Chik KW, Shing MM, Yuen PM. A Chinese adolescent girl with Fechtner-like syndrome. Acta. Paediatr. 87(6), 705-707 (1998). (Pubitemid 28331063)
97. Kahr WH, Savoia A, Pluthero FG et al. Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA. Thromb. Haemost. 102(6), 1241-1250 (2009).
98. Chen Z, Naveiras O, Balduini A et al. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood 110(1), 171-179 (2007). (Pubitemid 47026832)
99. Eckly A, Strassel C, Freund M et al. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation. Blood 113(14), 3182-3189 (2009).
100. Chang Y, Aurade F, Larbret F et al. Proplatelet formation is regulated by the Rho/ROCK pathway. Blood 109(10), 4229-4236 (2007). (Pubitemid 46743387)
101. Eckly A, Rinckel JY, Laeuffer P et al. Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice. J. Thromb. Haemost. 8(10), 2243-2251 (2010).
102. Noris P, Klersy C, Zecca M et al. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J. Thromb. Haemost. 7(12), 2131-2136 (2009).
103. Savoia A, De Rocco D, Panza E et al. Heavy chain myosin 9-related disease (MYH9-RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb. Haemost. 103(4), 826-832 (2010).
104. Kunishima S, Matsushita T, Kojima T et al. Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations. Lab. Invest. 83(1), 115-122 (2003). (Pubitemid 36126056)
105. Seri M, Cusano R, Gangarossa S et al. Mutations in MYH9 result in the May- Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/ Fechtner Syndrome Consortium. Nat. Genet. 26(1), 103-105 (2000).
106. Weiss HJ. Scott syndrome: a disorder of platelet coagulant activity. Semin. Hematol. 31(4), 312-319 (1994). (Pubitemid 24325183)
107. Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 468(7325), 834-838 (2010).
108. Weiss HJ. Impaired platelet procoagulant mechanisms in patients with bleeding disorders. Semin. Thromb. Hemost. 35(2), 233-241 (2009).
109. Weiss HJ, Vicic WJ, Lages BA, Rogers J. Isolated deficiency of platelet procoagulant activity. Am. J. Med. 67(2), 206-213 (1979). (Pubitemid 9239513)
110. Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden AT. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood 81(10), 2554-2565 (1993). (Pubitemid 23147557)
111. Cines DB, Bussel JB, McMillan RB, Zehnder JL. Congenital and acquired thrombocytopenia. Hematology Am. Soc. Hematol. Educ. Program 390-406 (2004).
112. King S, Germeshausen M, Strauss G, Welte K, Ballmaier M. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br. J. Haematol. 131(5), 636-644 (2005). (Pubitemid 43899631)
113. Geddis AE. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. Hematol. Oncol. Clin. North Am. 23(2), 321-331 (2009).
114. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 87(6), 2162-2170 (1996).
115. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 265(5177), 1445-1447 (1994). (Pubitemid 24306797)
116. Geddis AE, Kaushansky K. Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. Curr. Opin. Pediatr. 16(1), 15-22 (2004). (Pubitemid 38168156)
117. Ballmaier M, Germeshausen M, Schulze H et al. C-Mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 97(1), 139-146 (2001). (Pubitemid 32061253)
118. Klopocki E, Schulze H, Strauss G et al. Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome. Am. J. Hum. Genet. 80(2), 232-240 (2007). (Pubitemid 46175672)
119. Thompson AA, Woodruff K, Feig SA, Nguyen LT, Schanen NC. Congenital thrombocytopenia and radio-ulnar synostosis: a new familial syndrome. Br. J. Haematol. 113(4), 866-870 (2001). (Pubitemid 32634751)
120. Thompson AA, Nguyen LT. Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nat. Genet. 26(4), 397-398 (2000).
121. Horvat-Switzer RD, Thompson AA. HOXA11 mutation in amegakaryocytic thrombocytopenia with radio-ulnar synostosis syndrome inhibits megakaryocytic differentiation in vitro. Blood Cells Mol. Dis. 37(1), 55-63 (2006). (Pubitemid 44062358)
122. Nichols KE, Crispino JD, Poncz M et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat. Genet. 24(3), 266-270 (2000). (Pubitemid 30132195)
123. Mehaffey MG, Newton AL, Gandhi MJ, Crossley M, Drachman JG. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood 98(9), 2681-2688 (2001).
124. Freson K, Devriendt K, Matthijs G et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood 98(1), 85-92 (2001).
125. Hughan SC, Senis Y, Best D et al. Selective impairment of platelet activation to collagen in the absence of GATA1. Blood 105(11), 4369-4376 (2005). (Pubitemid 40720783)
126. Makris M, Conlon CP, Watson HG. Immunization of patients with bleeding disorders. Haemophilia 9(5), 541-546 (2003). (Pubitemid 37236087)
127. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann. Surg. 233(1), 88-96 (2001). (Pubitemid 32043608)
128. Coppola A, Di Minno G. Desmopressin in inherited disorders of platelet function. Haemophilia 14(Suppl. 1), 31-39 (2008).
129. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).J. Thromb. Haemost. 1(4), 682-689 (2003).
130. Balduini CL, Noris P, Belletti S, Spedini P, Gamba G. In vitro and in vivo effects of desmopressin on platelet function. Haematologica 84(10), 891-896 (1999). (Pubitemid 29516919)
131. Schulman S, Johnsson H, Egberg N, Blomback M. DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb. Res. 45(2), 165-174 (1987). (Pubitemid 17008084)
132. Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br. J. Haematol. 121(3), 477-481 (2003). (Pubitemid 36628341)
133. Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb. Haemost. 82(6), 1778 (1999).
134. Poon MC, D'Oiron R, Von Depka M et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J. Thromb. Haemost. 2(7), 1096-1103 (2004).
135. Dargaud Y, Bordet JC, Trzeciak MC, Vinciguerra C, Negrier C. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica 91(Suppl. 6), ECR20 (2006).
136. Hayward CP, Rao AK, Cattaneo M. Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia 12(Suppl. 3), 128-136 (2006).
137. Wilcox DA, White GC 2nd. Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia. J. Thromb. Haemost. 1(11), 2300-2311 (2003).
138. Boztug K, Schmidt M, Schwarzer A et al. Stem-cell gene therapy for the Wiskott- Aldrich syndrome. N. Engl. J. Med. 363(20), 1918-1927 (2010).
139. Macaulay IC, Carr P, Gusnanto A, Ouwehand WH, Fitzgerald D, Watkins NA. Platelet genomics and proteomics in human health and disease. J. Clin. Invest. 115(12), 3370-3377 (2005). (Pubitemid 43121821)
140. Rowley JW, Oler A, Tolley ND et al. Genome wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 10.1182/blood-2011-03-339705 (2011) (Epub ahead of print).